Pharmaceutical supply chain security is critical to ensuring that medicines reach patients in their intended form and are safe, effective, and authentic. Counterfeit or tampered products pose serious health risks, including treatment failure, drug resistance, and harmful side effects resulting from containing the wrong ingredients, wrong quantity of active ingredients, or additional harmful ingredients.[1] They may have been produced in unsanitary environments or by personnel not qualified to make medical products.[2] As global supply chains grow more complex, with multiple intermediaries and cross-border transactions, the potential for mishandling, criminal infiltration and fraud increases, making robust safeguards essential.[3]
The consequences of potential supply chain breaches extend beyond individual patients. The cost of counterfeit or substandard medicines to the U.S. health system is estimated to be over $30 billion annually.[4] These risks also threaten innovation by forcing companies to divert resources from research and development toward compliance and remediation.[5] Such associated costs include training and educating personnel about how to monitor and respond to reports of falsified or substandard medicines, investing in physical security measures to protect products through transport, and developing extensive information processing systems to provide end-to-end tracking of products to ensure visibility of legitimate products across the entire supply chain.[6]
A stable partnership between industry and government is vital to securing the pharmaceutical supply chain. Policies that mandate robust authentication standards, harmonize global regulations, and support advanced monitoring technologies will help detect and prevent illicit practices and protect patients.[7] By contrast, policies that introduce supply chain monitoring gaps or erode supply chain integrity standards increase the risk of patients being exposed to substandard or counterfeit medicines. Public-private collaboration can also strengthen enforcement against counterfeiters and improve data sharing to detect anomalies early.[8]
[1] FDA, “Counterfeit Medicine: Counterfeit Medicine May Be Harmful,” https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine.
[2] I. Syed & T. Milburn, “Rethinking counterfeit medical supply chains: a critical review of the current literature,” 3:3 Health Care Sciences 203 (2024).
[3] KPMG, “Third-party risks in the pharmaceutical supply chain” (2025), https://assets.kpmg.com/content/dam/kpmgsites/in/pdf/2025/03/third-party-risks-in-the-pharmaceutical-supply-chain.pdf.
[4] Syed & Milburn (2024).
[5] E. Melia, A. English, B. Naughton, “The impact of global falsified medicines regulation on healthcare stakeholders in the legitimate pharmaceutical supply chain: a systematic review” 11 Front Med. (2024).
[6] Melia et al. (2024).
[7] Raj et al. (2025).
[8] J. Sturchio & G. Cohen, “How PEPFAR’s Public-Private Partnerships Achieved Ambitious Goals, From Improving Labs to Strengthening Supply Chains” 31:7 Health Affairs (2012).